Tag: Biotech and Pharma

Bayer sells stake in contraceptives business to Apollo in €3bn financing deal

Bayer has agreed to sell a minority stake in its contraceptives business to Apollo Global Management in a €3bn deal, as the German pharmaceuticals group seeks to shore up its finances after years of costly US litigation over its Roundup weedkiller.

AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse

Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to meet its target, with analysts saying the bigger issue may be investors’ trust in the company rather than the loss of a few extra billion in sales.

This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal

Crinetics Pharmaceutical stock was surging on Tuesday after Vertex Pharmaceuticals said it had agreed to buy the biotech for $10 billion.

US House committee opens investigation into Merck, AbbVie China drug trials

A bipartisan group of U.S. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved ​in clinical trials conducted in China that helped fuel the communist country’s military capability, according to letters seen by Reuters.

French biotech stock soars 34% after new data on experimental medicine

Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease, clawing back heavy losses from earlier in the month when the same trial had investors questioning the drug’s future.

Lavipharm: H εξαγωγική δραστηριότητα θα ξεπερνά το 60% των πωλήσεων

Σύμφωνα με τα στοιχεία που παρουσιάστηκαν, οι πωλήσεις στο πρώτο εξάμηνο κινούνται με ρυθμό ανόδου της τάξης του 24%, επιβεβαιώνοντας τη δυναμική που έχει αναπτύξει ο όμιλος σε βασικές κατηγορίες προϊόντων και αγορές.

AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push

 AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, ​in its largest buyout in more than five years to strengthen its next-gen ‌immunology pipeline.

Nuvalent shares surge 39% after UK’s GSK agrees to buy the cancer drugmaker for $10.6 billion

Britain’s second-largest drugmaker GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its oncology pipeline, in what would be its largest acquisition in more than a decade.

Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug

Eli Lilly shares jumped in premarket trade on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts.

Weight loss drug maker sinks 25% after new safety data spooks investors

Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after new data on its experimental medicine raised concerns over its potential side effects.

Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine

Moderna said on Monday it has ​partnered with a global health coalition to develop a potential ‌vaccine against Bundibugyo ebolavirus, the strain linked to the ongoing Ebola outbreak in eastern Democratic Republic of Congo.

Lavipharm: Ολοκλήρωση της συναλλαγής για την απόκτηση του DUROGESIC

Η Lavipharm Α.Ε. ανακοινώνει την ολοκλήρωση της συναλλαγής για την απόκτηση των Αδειών Κυκλοφορίας, των εμπορικών σημάτων και των δικαιωμάτων εμπορικής εκμετάλλευσης και παραγωγής του DUROGESIC® από την Janssen Global Services LLC

Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion

Eli Lilly & Co. agreed to buy three vaccine developers for a total of up to about $3.8 billion, marking the drugmaker’s re-entry into the infectious disease space.

Biogen to advance experimental Alzheimer’s drug despite mid-stage trial miss

Biogen (BIIB.O), will advance its experimental Alzheimer’s drug to late-stage ​development after a mid-stage study showed it slowed mental decline and reduced ‌a key brain protein linked to the disease, although it failed to meet the trial’s main goal.

Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance

Telehealth company Hims & Hers’ stock plummeted in early trading Tuesday after posting a first-quarter loss and weak earnings guidance for the year ahead.

Novo Nordisk’s weight-loss pill exceeds forecasts, closing gap with Lilly

Novo Nordisk, opens new tab beat first-quarter profit forecasts and nudged up its full-year outlook on Wednesday, helped by stronger-than-expected sales of its new weight-loss pill ‌as it seeks to close the gap with U.S. rival Eli Lilly.

Pfizer Stock Rises on Earnings. The Drugmaker Is Finding Life After Covid.

Pfizer shares climbed on Tuesday after the company delivered a first-quarter earnings beat and reaffirmed its full-year outlook.

Moderna Stock Spikes After Earnings. Covid Vaccine Revenue Is a Growth Driver Again.

Moderna defied expectations of a Covid-revenue slowdown on Friday as the drugmaker delivered strong first-quarter results fueled by a surge in international vaccine sales.

Bristol-Myers Squibb trumps Q1 estimates, maintains full-year outlook

Bristol-Myers Squibb reported first-quarter earnings and revenue that topped analyst expectations, and reaffirmed its outlook for the full year.

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket

Shares of Eli Lilly (LLY) rose sharply Thursday after the drugmaker delivered a beat-and-raise quarter driven partly by demand for its GLP-1 drugs.